254 related articles for article (PubMed ID: 16412852)
1. Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes.
Lenderink T; Heeschen C; Fichtlscherer S; Dimmeler S; Hamm CW; Zeiher AM; Simoons ML; Boersma E;
J Am Coll Cardiol; 2006 Jan; 47(2):307-11. PubMed ID: 16412852
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of placental growth factor in patients with acute chest pain.
Heeschen C; Dimmeler S; Fichtlscherer S; Hamm CW; Berger J; Simoons ML; Zeiher AM;
JAMA; 2004 Jan; 291(4):435-41. PubMed ID: 14747500
[TBL] [Abstract][Full Text] [Related]
3. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
Hamm CW; Heeschen C; Goldmann B; Vahanian A; Adgey J; Miguel CM; Rutsch W; Berger J; Kootstra J; Simoons ML
N Engl J Med; 1999 May; 340(21):1623-9. PubMed ID: 10341274
[TBL] [Abstract][Full Text] [Related]
4. Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome.
Oemrawsingh RM; Lenderink T; Akkerhuis KM; Heeschen C; Baldus S; Fichtlscherer S; Hamm CW; Simoons ML; Boersma E;
Heart; 2011 Jul; 97(13):1061-6. PubMed ID: 21558475
[TBL] [Abstract][Full Text] [Related]
5. Soluble CD40 ligand in acute coronary syndromes.
Heeschen C; Dimmeler S; Hamm CW; van den Brand MJ; Boersma E; Zeiher AM; Simoons ML;
N Engl J Med; 2003 Mar; 348(12):1104-11. PubMed ID: 12646667
[TBL] [Abstract][Full Text] [Related]
6. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis.
Heeschen C; Dimmeler S; Hamm CW; Fichtlscherer S; Simoons ML; Zeiher AM;
J Am Coll Cardiol; 2005 Jan; 45(2):229-37. PubMed ID: 15653020
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial.
Heeschen C; Hamm CW; Bruemmer J; Simoons ML
J Am Coll Cardiol; 2000 May; 35(6):1535-42. PubMed ID: 10807457
[TBL] [Abstract][Full Text] [Related]
8. Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA.
Lenderink T; Boersma E; Heeschen C; Vahanian A; de Boer MJ; Umans V; van den Brand MJ; Hamm CW; Simoons ML;
Eur Heart J; 2003 Jan; 24(1):77-85. PubMed ID: 12559939
[TBL] [Abstract][Full Text] [Related]
9. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes.
Baldus S; Heeschen C; Meinertz T; Zeiher AM; Eiserich JP; Münzel T; Simoons ML; Hamm CW;
Circulation; 2003 Sep; 108(12):1440-5. PubMed ID: 12952835
[TBL] [Abstract][Full Text] [Related]
10. Utility of placental growth factor for prediction of 30-day adverse event in emergency department population with non-ST elevation acute coronary syndrome.
Marković M; Ignjatović S; Dajak M; Majkić-Singh N
Clin Lab; 2010; 56(5-6):215-22. PubMed ID: 20575469
[TBL] [Abstract][Full Text] [Related]
11. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction.
Aviles RJ; Askari AT; Lindahl B; Wallentin L; Jia G; Ohman EM; Mahaffey KW; Newby LK; Califf RM; Simoons ML; Topol EJ; Berger P; Lauer MS
N Engl J Med; 2002 Jun; 346(26):2047-52. PubMed ID: 12087140
[TBL] [Abstract][Full Text] [Related]
12. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18.
Morrow DA; Sabatine MS; Brennan ML; de Lemos JA; Murphy SA; Ruff CT; Rifai N; Cannon CP; Hazen SL
Eur Heart J; 2008 May; 29(9):1096-102. PubMed ID: 18339606
[TBL] [Abstract][Full Text] [Related]
13. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
Kastrati A; Mehilli J; Neumann FJ; Dotzer F; ten Berg J; Bollwein H; Graf I; Ibrahim M; Pache J; Seyfarth M; Schühlen H; Dirschinger J; Berger PB; Schömig A;
JAMA; 2006 Apr; 295(13):1531-8. PubMed ID: 16533938
[TBL] [Abstract][Full Text] [Related]
14. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
Popma JJ; Satler LF
J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
[TBL] [Abstract][Full Text] [Related]
15. 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome.
Damman P; Hirsch A; Windhausen F; Tijssen JG; de Winter RJ;
J Am Coll Cardiol; 2010 Mar; 55(9):858-64. PubMed ID: 20045278
[TBL] [Abstract][Full Text] [Related]
16. A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes.
Roe MT; Christenson RH; Ohman EM; Bahr R; Fesmire FM; Storrow A; Mollod M; Peacock WF; Rosenblatt JA; Yang H; Fraulo ES; Hoekstra JW; Gibler WB; ;
Am Heart J; 2003 Dec; 146(6):993-8. PubMed ID: 14660990
[TBL] [Abstract][Full Text] [Related]
17. Treatment modalities of non-ST-elevation acute coronary syndromes in the real world. Results of the prospective R.OS.A.I.-2 registry.
Registro Osservazionale Angina Instabile Investigators
Ital Heart J; 2003 Nov; 4(11):782-90. PubMed ID: 14699708
[TBL] [Abstract][Full Text] [Related]
18. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
Vavuranakis M; Latsios G; Aggelis D; Bosinakou I; Karambelas I; Tousoulis D; Toutouzas K; Stefanadis C
Clin Ther; 2006 Jun; 28(6):860-71. PubMed ID: 16860169
[TBL] [Abstract][Full Text] [Related]
19. Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and their association with clinical outcome, troponin T and C-reactive protein in patients with acute coronary syndromes.
Postadzhiyan AS; Tzontcheva AV; Kehayov I; Finkov B
Clin Biochem; 2008 Feb; 41(3):126-33. PubMed ID: 18061588
[TBL] [Abstract][Full Text] [Related]
20. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
